Form 4: Soleno Therapeutics CEO Anish Bhatnagar Sells Shares to Cover Tax Obligations

CEO of Soleno Therapeutics, Anish Bhatnagar, sold shares of common stock between August 5th and August 6th, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• Anish Bhatnagar, the CEO of Soleno Therapeutics, sold shares of the company's common stock on August 5th and 6th, 2024.
• The sales were executed in multiple transactions at varying prices.
• These sales were conducted to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs).
• Following these transactions, Bhatnagar still beneficially owns a significant number of Soleno Therapeutics shares.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to stock sales for tax purposes, which is neither particularly positive nor negative.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders due to the increased supply of shares in the market, but the impact is likely to be minimal given the purpose of the sales.

Key Dates